Adult stem cell

BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update

Retrieved on: 
Thursday, November 14, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Adult stem cell, Draft:BrainStorm Cell Therapeutics, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting

Retrieved on: 
Tuesday, November 12, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cloning, Developmental biology, Adult stem cell

( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Companys Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting , which is hosted by the Israel Stem Cell Society .

Key Points: 
  • ( NASDAQ:BCLI ), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Companys Chief Operating and Chief Medical Officer Ralph Kern MD MHSc will present at the 7th International Stem Cell Meeting , which is hosted by the Israel Stem Cell Society .
  • Ralph Kern, MD, MHSc, said: I welcome the opportunity to participate in the 7th International Stem Cell Meeting where I will share the advances BrainStorm has made with NurOwn.
  • It is a privilege to participate and to exchange ideas with many of the international scientific leaders in stem cell research.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update

Retrieved on: 
Tuesday, November 5, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Developmental biology, Induced stem cells, Cell biology, Mesenchymal stem cell, Adult stem cell, Cellular differentiation, Draft:BrainStorm Cell Therapeutics

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program

Retrieved on: 
Wednesday, October 23, 2019
Branches of biology, Biology, Life sciences, Connective tissue, Obesity, Biotechnology, Cell biology, Brown adipose tissue, Adipose tissue, Stem cell, Adult stem cell, Ciberobn

This is the second patent issued for the Companys brown fat technology in Australia and adds to three other patents related to BioRestoratives metabolic program (ThermoStem Program) that have previously been issued to the Company in the United States and other countries.

Key Points: 
  • This is the second patent issued for the Companys brown fat technology in Australia and adds to three other patents related to BioRestoratives metabolic program (ThermoStem Program) that have previously been issued to the Company in the United States and other countries.
  • This patent, granted by the Australian Patent Office for our metabolic program, adds to our growing family of IP surrounding and protecting our brown fat metabolic cell program, said Mark Weinreb, CEO of BioRestorative Therapies.
  • BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells.
  • Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT).

BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit

Retrieved on: 
Wednesday, October 23, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Adult stem cell, Draft:BrainStorm Cell Therapeutics, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors.
  • NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS.

Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights

Retrieved on: 
Monday, October 7, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Stem-cell therapy, Adult stem cell, Cell therapy, Induced pluripotent stem cell, Stem-cell line

A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.

Key Points: 
  • A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.
  • By Therapy it can be classified as Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
  • By Product it can be classified as Very Small Embryonic like Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, and Adult Stem Cells.
  • Browse 190 page research report with TOC on "Global Stem Cells Market" at: https://www.millioninsights.com/industry-reports/stem-cells-market
    Stem Cell Product Outlook (Revenue, USD Billion, 2014 - 2025)

Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights

Retrieved on: 
Monday, October 7, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Cell biology, Emerging technologies, Stem-cell therapy, Adult stem cell, Cell therapy, Induced pluripotent stem cell, Stem-cell line

A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.

Key Points: 
  • A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years.
  • By Therapy it can be classified as Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
  • By Product it can be classified as Very Small Embryonic like Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, and Adult Stem Cells.
  • Browse 190 page research report with TOC on "Global Stem Cells Market" at: https://www.millioninsights.com/industry-reports/stem-cells-market
    Stem Cell Product Outlook (Revenue, USD Billion, 2014 - 2025)

BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting

Retrieved on: 
Wednesday, October 2, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Mesenchymal stem cell, Adult stem cell, Draft:BrainStorm Cell Therapeutics, Stem-cell therapy

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • BrainStorm is currently conducting a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis.

Gene-edited, stem cell reporter line could boost cardiac research

Retrieved on: 
Monday, September 30, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cloning, Developmental biology, Embryonic stem cell, Stem-cell niche, Royan Institute, Adult stem cell

A study released today in STEM CELLS details the development of one such line, CRISPR-generated ArcLight-hiPSCs.

Key Points: 
  • A study released today in STEM CELLS details the development of one such line, CRISPR-generated ArcLight-hiPSCs.
  • The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research.
  • STEM CELLS TRANSLATIONAL MEDICINE ( http://www.StemCellsTM.com ) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology.
  • By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.

Study indicates early infusion of mononuclear cells could aid in recovery from stroke

Retrieved on: 
Tuesday, September 17, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Embryonic stem cell, Induced pluripotent stem cell, Cancer stem cell, Stem-cell therapy, Adult stem cell

The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery.

Key Points: 
  • The regenerative potential of BM-derived MNCs is attributed to various mechanisms that impact stroke recovery.
  • Well-designed random clinical trials are needed to further assess safety and efficacy of this novel approach to enhance stroke recovery."
  • "New options to treat Ischemic stroke are desperately needed," said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS.
  • The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research.